TY - JOUR
T1 - Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging
AU - Minamimoto, Ryogo
AU - Mosci, Camila
AU - Jamali, Mehran
AU - Barkhodari, Amir
AU - Habte, Frezghi
AU - Jackson, Tatianie
AU - Mittra, Erik
AU - Gambhir, Sanjiv Sam
AU - Iagaru, Andrei
N1 - Publisher Copyright:
COPYRIGHT © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - In this study, we evaluated the biodistribution of the 18F-/18F-FDG administration, compared with separate 18F-NaF and 18F-FDG administrations. We also estimated the interaction of 18F-NaF and 18F-FDG in the 18F-/18F-FDG administration by semiquantitative analysis. Methods: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate 18F-FDG PET/CT and 18F-NaF PET/CT scans as well as 18F-/18F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n 5 28), followed by sarcoma (n 5 9) and breast cancer (n 5 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the 18F-/18F-FDG uptake as the sum of18F-FDG uptake and adjusted 18F-NaF uptake based on the ratio of18F-NaF injected dose in 18F-/18F-FDG PET/CT. Lastly, we compared the results to explore the interaction of 18F-FDG and18F-NaF uptake in the 18F-/18F-FDG scan. Results: The18F-/18F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the18F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the 18F-FDG and the 18F-NaF uptake. The 18F-/18F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate18F-FDG scan. The18F-/18F-FDG uptake in skeletal lesions reflected mostly the 18F-NaF uptake. The tumor-to-background ratio of 18F-/18F-FDG in extraskeletal lesions showed no significant difference when compared with that from 18F-FDG alone (P 5 0.73). For skeletal lesions, the tumor-to-background ratio of 18F-/18F-FDG was lower than that from 18F-NaF alone (P , 0.001); however, this difference did not result in missed skeletal lesions on the 18F-/18F-FDG scan. Conclusion: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the 18F-/18F-FDG scan as well as the variations compared with the uptake on the separate 18F-FDG PET/CT and 18F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.
AB - In this study, we evaluated the biodistribution of the 18F-/18F-FDG administration, compared with separate 18F-NaF and 18F-FDG administrations. We also estimated the interaction of 18F-NaF and 18F-FDG in the 18F-/18F-FDG administration by semiquantitative analysis. Methods: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate 18F-FDG PET/CT and 18F-NaF PET/CT scans as well as 18F-/18F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n 5 28), followed by sarcoma (n 5 9) and breast cancer (n 5 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the 18F-/18F-FDG uptake as the sum of18F-FDG uptake and adjusted 18F-NaF uptake based on the ratio of18F-NaF injected dose in 18F-/18F-FDG PET/CT. Lastly, we compared the results to explore the interaction of 18F-FDG and18F-NaF uptake in the 18F-/18F-FDG scan. Results: The18F-/18F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the18F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the 18F-FDG and the 18F-NaF uptake. The 18F-/18F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate18F-FDG scan. The18F-/18F-FDG uptake in skeletal lesions reflected mostly the 18F-NaF uptake. The tumor-to-background ratio of 18F-/18F-FDG in extraskeletal lesions showed no significant difference when compared with that from 18F-FDG alone (P 5 0.73). For skeletal lesions, the tumor-to-background ratio of 18F-/18F-FDG was lower than that from 18F-NaF alone (P , 0.001); however, this difference did not result in missed skeletal lesions on the 18F-/18F-FDG scan. Conclusion: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the 18F-/18F-FDG scan as well as the variations compared with the uptake on the separate 18F-FDG PET/CT and 18F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.
KW - PET/CT
KW - SUV
KW - f-fdg
KW - f-naf
UR - http://www.scopus.com/inward/record.url?scp=84929456902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929456902&partnerID=8YFLogxK
U2 - 10.2967/jnumed.115.153767
DO - 10.2967/jnumed.115.153767
M3 - Article
C2 - 25840978
AN - SCOPUS:84929456902
SN - 0161-5505
VL - 56
SP - 688
EP - 694
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 5
ER -